Santa Clara, California, May 28, 2024 SAN FRANCISCO, Oct. 13, 2020 /PRNewswire/ — Semler Scientific Corporation (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to help healthcare professionals combat chronic disease, today announced that its Board of Directors has Bitcoin Semler Scientific has announced that it has purchased a total of 581 Bitcoins, which it holds as its primary treasury reserve asset. $40 millionIncludes fees and expenses.
“our Bitcoin Financial Strategy and Purchasing Bitcoin Emphasizing our beliefs Bitcoin It is a reliable store of value and an attractive investment.” Eric SemlerChairman of Semler Scientific.Bitcoin It is now a major asset class. $1 trillion It is worth about 10 times its market value. We believe gold has unique characteristics as a scarce and finite asset that can act as a reasonable inflation hedge and safe haven during times of global uncertainty. We also believe it is superior to gold because it is digital and structurally resilient. It is worth about 10 times its market value. BitcoinConsidering the difference in value between gold and silver Bitcoinwe believe, Bitcoin As it becomes more and more accepted as digital gold, it has the potential to generate huge profits.
“Furthermore, we Bitcoin — Most recently, the Securities and Exchange Commission January 2024 11 Approvals Bitcoin Exchange-traded funds. These funds are: $13 billion “Net inflows came from approximately 1,000 institutions, including global banks, pension funds, endowments and registered investment advisors. We estimate that more than 10% of all Bitcoin is now held by institutional investors,” Semler added.
Semler Scientific's board of directors and senior management spent considerable time considering potential uses for the cash, including acquisitions. “After considering various options, we have decided to proceed with the acquisition,” the company said in a statement. Bitcoin “It's the best use of excess funds,” Semler said.
In relation to that Bitcoin Semler Scientific's financial strategy will continue to focus on its core medical products and services. “Our goal of operating a growing, profitable healthcare company and our dedication to our customers remain unchanged,” Semler Scientific said. Doug Murphy Chutrian“We are committed to maintaining sales of QuantaFlo® for peripheral artery disease testing while seeking new 510(k) clearance from the FDA with an expanded label for use as an aid in the diagnosis of other cardiovascular diseases,” said Semler Scientific's Chief Executive Officer, M.D.
As Semler Scientific continues to generate revenue and free cash flow from the sale of QuantaFlo, we will actively evaluate uses of excess cash. Bitcoin It will continue to serve as Semler Scientific's primary financial holding on an ongoing basis, subject to market conditions and Semler Scientific's expected cash needs.
More information on Semler Scientific Bitcoin The financial strategy will be published on the website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific develops, manufactures and markets innovative products and services to combat chronic disease. The company's flagship product, QuantaFlo®, is a patented and cleared by the U.S. Food and Drug Administration (FDA) rapid point-of-care test that measures arterial blood flow in the limbs. The QuantaFlo test helps diagnose cardiovascular diseases such as peripheral artery disease (PAD), and Semler Scientific is currently seeking new 510(k) clearance for an expanded indication. QuantaFlo is used by healthcare professionals to assess a patient's risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific is a Bitcoin And adopted Bitcoin Semler Scientific considers this to be its primary financial reserve. Additional information about Semler Scientific can be found at www.semlerscientific.com.
Forward-Looking Statements
This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking words such as “believe,” “goals,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “plan,” “will,” “can” or words of similar meaning or the negative of these words or discussions of strategy or intentions. Forward-looking statements in this release may include, but are not limited to, statements regarding new Bitcoin Strategy and its ability to generate significant profits, information on the website Bitcoin and obtaining additional 510(k) clearances for expanded indications for QuantaFlo. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed herein, including, but not limited to, the Company's ongoing efforts to develop and commercialize its products and services, including the acquisition of new 510(k) clearances for additional indications for QuantaFlo. Bitcoininclude BitcoinThese forward-looking statements include, but are not limited to, the volatility of future business developments, the risk of implementing new financial strategies, the risk that insurance plans and other customers will not continue to license the company's cardiovascular testing products, the risk of changes in reimbursement status for customers, including related to CMS fee announcements, the risk of obtaining new 510(k) clearance for expanded indications, and other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates and uncertainties that reflect current internal expectations, expectations or beliefs. There can be no assurance that such statements will prove accurate, and actual results and future events may differ materially from those anticipated in such statements. All forward-looking statements included in this press release are qualified in their entirety by these cautionary statements and the risk factors set forth above. Furthermore, all such statements are made as of the date of this release, and Semler Scientific does not undertake any obligation to update or revise such statements, unless otherwise required by law.
Investor contact:
Renae Cormier
CFO
[email protected]
SOURCE Semler Scientific, Inc.
